NEW YORK, May 30, 2024 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Biogen Inc. ("Biogen" or the "Company") (NASDAQ: BIIB) and certain officers. The class action, filed in the United States District Court for the District of Colorado, and docketed under 24-cv-01444, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Biogen securities between February 3, 2022 and February 13, 2024, both dates ...

SOD1-ALS is a devastating, uniformly fatal, and ultra-rare genetic form of ALS estimated to affect less than 1,000 people in Europe1QALSODY is Biogen's third rare disease therapy to be approved in the EU, demonstrating the company's commitment to addressing diseases with a high unmet needWith QALSODY, Biogen has helped advance neurofilament as a tool to optimize clinical trial design in ALS, offering the potential to expedite further breakthroughs in the field CAMBRIDGE, Mass., May 30, 2024 (GLOBE NEWSWIRE) ...

SOD1-ALS is a devastating, uniformly fatal, and ultra-rare genetic form of ALS estimated to affect less than 1,000 people in Europe1QALSODY is Biogen’s third rare disease therapy to be approved in the EU, demonstrating the company’s commitment to addressing diseases with a high unmet needWith QALSODY, Biogen has helped advance neurofilament as a tool to optimize clinical trial design in ALS, offering the potential to expedite further breakthroughs in the field CAMBRIDGE, Mass., May 30, 2024 (GLOBE NEWSWIRE) ...

Jeito Capital announces the acquisition by Merck & Co (NYSE:MRK)of its portfolio company EyeBio for a potential value of $3 billion This acquisition reflects the significant clinical progress achieved with Restoret™, EyeBio's novel late-phase candidate for diabetic macular edema, as well as a preclinical pipeline targeting retinal diseases - Restoret anticipated to enter pivotal study for diabetic macular edema in the second half of 2024 The acquisition by Merck & Co (NYSE:MRK), a global biopharmaceutical c ...

文章核心观点 - Biogen Inc. (BIIB) 的最新财报显示，第一季度业绩喜忧参半，每股收益超出预期，但销售额未达预期。公司股价在过去一个月内上涨了约7.7%，表现优于标准普尔500指数。[1] 第一季度业绩 - 第一季度调整后每股收益（EPS）为$3.67，超出Zacks共识预期$3.45，同比增长8%，主要得益于成本节约和利润率改善。在固定汇率基础上，收益持平。[2] - 总收入为$22.9亿美元，同比下降7%，主要由于Tecfidera、Tysabri和Spinraza销售额下降。新推出的Leqembi、Skyclarys和Zurzuvae在第一季度有所增长。销售额未达到Zacks共识预期的$23.2亿美元。[2] - 产品销售额为$17.1亿美元，同比下降3%。抗CD20治疗项目的收入下降1%至$3.94亿美元。合同制造和特许权使用费收入下降39%至$1.846亿美元。[2][3] 多发性硬化症（MS）收入 - 多发性硬化症收入为$10.8亿美元，同比下降4%，主要由于Tecfidera的仿制药竞争和MS市场的竞争加剧。Tecfidera销售额下降7.4%至$2.543亿美元，但超出预期。Vumerity销售额增长18%至$1.275亿美元，Tysabri销售额下降9%至$4.313亿美元。[4][5] 罕见病药物 - Spinraza销售额下降23%至$3.413亿美元，主要由于美国以外市场的销售额下降。Skyclarys销售额为$7800万美元，环比增长。Qalsody销售额为$460万美元，环比增长。[7][8] 其他产品 - 生物仿制药收入增长2%至$1.969亿美元。预计2024年生物仿制药收入增长将较为温和。[9] 成本下降 - 研发费用下降22%至$4.47亿美元，调整后的销售、一般和管理费用下降6%至$5.69亿美元。[10] 2024年指引 - 管理层重申了2024年的指引，预计总收入将同比下降低至中个位数百分比。核心制药收入预计将持平，合同制造收入将显著下降。预计2024年调整后每股收益在$15.00至$16.00之间，同比增长约5%。[12][13] 市场反应 - 过去一个月，投资者见证了估计修订的下降趋势。Biogen的Zacks排名为3（持有），预计未来几个月股价将持平。[14][16]

NEW YORK, May 23, 2024 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Biogen Inc. ("Biogen Inc." or "the Company") (NASDAQ: BIIB) and certain of its officers.Class Definition:This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Biogen Inc. securi ...

LOS ANGELES, May 23, 2024 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Biogen Inc. ("Biogen" or "the Company") (NASDAQ: BIIB) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between February 3, 2022 and February 13, 2024, inclusive (the "Class Period"), are en ...

Biogen (BIIB) entered into a definitive agreement to acquire private biotech, HI-Bio, for a $1.15 billion upfront payment.The acquisition will expand Biogen’s rare disease pipeline by adding Hi-Bio’s lead candidate, felzartamab, a promising late-stage ready asset with potential application across a range of rare immune-mediated diseases. Felzartamab, a fully human anti-CD38 monoclonal antibody, has demonstrated an impact on key biomarkers and clinical endpoints in three renal diseases.Felzartamab is being d ...

Key TakeawaysBiogen has agreed to pay at least $1.15 billion for biotech firm Human Immunology Biosciences (HI-Bio) as it moves to increase its immunology portfolio.The deal includes the possibility of an additional $650 million in milestone payments. HI-Bio's lead asset treats rare kidney diseases. Biogen (BIIB) announced Wednesday it had purchased privately-held Human Immunology Biosciences (HI-Bio) for at least $1.15 billion to expand its reach into immunology medicines.  The company said that the $1.15 ...

NEW YORK, May 22, 2024 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Biogen Inc. ("Biogen" or the"Company") (NASDAQ: BIIB) and certain officers. The class action, filed in the United States District Court for the District of Colorado, and docketed under 24-cv-01444, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Biogen securities between February 3, 2022 and February 13, 2024, both dates i ...